Categories: DNANews

Wave Life Sciences to Webcast Conference Call of Third Quarter 2022 Financial Results on November 10, 2022

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

CAMBRIDGE, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webcast and conference call at 8:30 a.m. ET on Thursday, November 10, 2022, to discuss the company’s third quarter 2022 financial results and provide a business update.

The webcast of the conference call may be accessed by visiting “Events” at the investor relations section of the Wave Life Sciences corporate website: ir.wavelifesciences.com.

Participants planning to ask a question during the Q&A portion of the live call can join the webcast at the following audio conferencing link: https://register.vevent.com/register/BI3c61006b6de34cd6a3924918ba54e58f.

Following the conference call, an archived version of the call will be available on the website.

About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company’s proprietary discovery and drug development platform that enables the precise design, optimization, and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future. To find out more, please visit www.wavelifesciences.com and follow Wave on Twitter @WaveLifeSci.

Investor Contact:
Kate Rausch
617-949-4827
krausch@wavelifesci.com

Media Contact:
Alicia Suter
617-949-4817
asuter@wavelifesci.com

Staff

Recent Posts

Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis

Designed to assess the impact of CardiolRx™ on preventing episodes of recurrent pericarditis, the first…

9 minutes ago

Therma Bright Reviews Manufacturing Strategy in Light of US Tariff Changes

Toronto, Ontario--(Newsfile Corp. - April 16, 2025) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF)…

1 hour ago

Healthera secures £2m strategic investment to accelerate digital pharmacy platform growth and North American expansion

An additional £2 million in new funding from private investors takes the company's Series A…

2 hours ago

Ministry of Health Kuwait Enhances Collaboration with Intalio’s Correspondence Management System

KUWAIT CITY, Kuwait, April 16, 2025 /PRNewswire/ -- In a significant step toward enhancing operational…

2 hours ago

What if Your SOAP Notes Wrote Themselves? DentScribe.ai’s AI Captures Dental Jargon for Perfect, Real-Time Charting

SUNNYVALE, Calif., April 16, 2025 /PRNewswire/ -- Imagine finishing a dental procedure and seeing a…

2 hours ago

The 8th China EdFest Gives Parents a Powerful Voice

SHANGHAI, April 16, 2025 /PRNewswire/ -- The 8th China Festival of Education, hosted by Wellington College…

2 hours ago